secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210413
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara biotherapeutics gets FDA alignment on tab-cel BLA resubmission path
-------------------------------------------------------------------------

- Type A meeting with FDA was productive; FDA agreed single-arm study with historical control could support future application.
- Pierre Fabre to submit updated ALLELE study dataset with more patients and longer follow-up as part of resubmission.
- Tabelecleucel is for R/R EBV+ PTLD post solid organ or hematopoietic cell transplant.
- Company expects to provide further regulatory update in Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/0001193125-26-210413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/atra-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer